← Browse by Condition
Medical Condition

solid tumor

Total Trials
41
Recruiting Now
41
Trial Phases
Phase 1, Phase 1, Phase 2, EARLY_Phase 1

ClinicalMetric tracks all active clinical trials for solid tumor sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — solid tumor Clinical Trials

How many clinical trials are currently recruiting for solid tumor?
ClinicalMetric currently tracks 41 actively recruiting clinical trials for solid tumor, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 41. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for solid tumor?
solid tumor research spans Phase 1 (33 trials), Phase 2 (11 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a solid tumor clinical trial?
Eligibility criteria for solid tumor trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
33
Phase 2
11
Top Sponsors
Hua Zhu 2 trials
National Cancer Centre, Singapore 2 trials
M.D. Anderson Cancer Center 2 trials
Binhui Biopharmaceutical Co., Ltd. 2 trials
Lei Zheng 1 trial

Recruiting Clinical Trials

NCT07086768 Phase 1
Recruiting
Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors
Enrollment
57 pts
Location
United States
Sponsor
Lei Zheng
View Trial →
NCT06712680 Phase 1, Phase 2
Recruiting
A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes
Enrollment
115 pts
Location
China
Sponsor
Sichuan Huiyu Pharmaceutical C...
View Trial →
NCT06307249 Phase 1
Recruiting
Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
Enrollment
50 pts
Location
Lebanon
Sponsor
Lebanese University
View Trial →
NCT06384807 Phase 1, Phase 2
Recruiting
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
Enrollment
500 pts
Location
United States
Sponsor
Biohaven Therapeutics Ltd.
View Trial →
NCT06239298 Phase 1, Phase 2
Recruiting
A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor
Enrollment
130 pts
Location
China
Sponsor
Suzhou Zelgen Biopharmaceutica...
View Trial →
NCT06619587 Phase 1
Recruiting
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
Enrollment
410 pts
Location
United States, Austr...
Sponsor
Genentech, Inc.
View Trial →
NCT04064359 Phase 1
Recruiting
Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors
Enrollment
200 pts
Location
United States, Belgi...
Sponsor
Oxford BioTherapeutics Ltd
View Trial →
NCT06248697 EARLY_Phase 1
Recruiting
Exploratory Study of MSLN-CAR T Cells Secreting PD1/CTLA-4 Nanoantibody for the Treatment of Advanced Solid Tumors
Enrollment
16 pts
Location
China
Sponsor
Shanghai Cell Therapy Group Co...
View Trial →
NCT06429891
Recruiting
Research on Early Diagnosis and Clinical Transformation of Nuclide Probe Based on Bioorthogonal-gastric Cancer Mucin Target Visualization
Enrollment
50 pts
Location
China
Sponsor
Hua Zhu
View Trial →
NCT05985161 Phase 2
Recruiting
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Enrollment
45 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →
NCT05244551 Phase 1
Recruiting
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors
Enrollment
85 pts
Location
United States, China
Sponsor
Abbisko Therapeutics Co, Ltd
View Trial →
NCT05584670 Phase 1, Phase 2
Recruiting
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Enrollment
542 pts
Location
United States, Chile...
Sponsor
Sanofi
View Trial →
NCT05868226 Phase 1
Recruiting
PRE-I-SPY Phase I/Ib Oncology Platform Program
Enrollment
124 pts
Location
United States
Sponsor
QuantumLeap Healthcare Collabo...
View Trial →
NCT06375187 Phase 1
Recruiting
A Study of GC203 TIL in Advanced Malignant Solid Tumors
Enrollment
18 pts
Location
China
Sponsor
Shanghai Juncell Therapeutics
View Trial →
NCT06883149 Phase 1
Recruiting
PIN in Combination With Anti-PD1 in Previously Treated Solid Tumor
Enrollment
25 pts
Location
China
Sponsor
Chinese PLA General Hospital
View Trial →
NCT06956248
Recruiting
Innovating Access to Novel Therapies Through Standardized Prospective Integration of Response Evaluations (IMPACT-INSPIRE)
Enrollment
50 pts
Location
Singapore
Sponsor
National Cancer Centre, Singap...
View Trial →
NCT06809114 Phase 1
Recruiting
FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors
Enrollment
83 pts
Location
United States
Sponsor
Axcynsis Therapeutics Pte Ltd
View Trial →
NCT06515626 EARLY_Phase 1
Recruiting
Genetically Modified T Cells Treating Malignant Tumors
Enrollment
100 pts
Location
China
Sponsor
Yi Zhang
View Trial →
NCT04930432 Phase 1, Phase 2
Recruiting
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Enrollment
400 pts
Location
China
Sponsor
Betta Pharmaceuticals Co., Ltd...
View Trial →
NCT04196257 Phase 1
Recruiting
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Enrollment
50 pts
Location
United States
Sponsor
Bio-Path Holdings, Inc.
View Trial →
NCT02806388
Recruiting
Individualized Molecular Profiling for Allocation to Clinical Trials (IMPACT) Project
Enrollment
5,500 pts
Location
Singapore
Sponsor
National Cancer Centre, Singap...
View Trial →
NCT06342336 Phase 1
Recruiting
HS-IT101 Injection in the Treatment of Advanced Solid Tumors
Enrollment
44 pts
Location
China
Sponsor
Qingdao Sino-Cell Biomedicine ...
View Trial →
NCT05525858
Recruiting
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Enrollment
1,000 pts
Location
South Korea
Sponsor
Seoul National University Bund...
View Trial →
NCT04796012 Phase 1, Phase 2
Recruiting
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
Enrollment
23 pts
Location
United States
Sponsor
University of Texas Southweste...
View Trial →
NCT06576037 Phase 1
Recruiting
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
Enrollment
128 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT06440005 Phase 1
Recruiting
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Enrollment
80 pts
Location
United States
Sponsor
Angiex, Inc.
View Trial →
NCT05250284
Recruiting
The Intersection of Oncology Care and Worker Well-Being
Enrollment
400 pts
Location
United States
Sponsor
University of Colorado, Denver
View Trial →
NCT07382531 Phase 1, Phase 2
Recruiting
OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors
Enrollment
30 pts
Location
China
Sponsor
Binhui Biopharmaceutical Co., ...
View Trial →
NCT06475131 Phase 1
Recruiting
A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors
Enrollment
21 pts
Location
China
Sponsor
Sichuan Baili Pharmaceutical C...
View Trial →
NCT06586957 Phase 1
Recruiting
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Enrollment
150 pts
Location
United States
Sponsor
NiKang Therapeutics, Inc.
View Trial →
NCT05423262 Phase 1, Phase 2
Recruiting
A Study of TRK-950 in Patients With Advanced Solid Tumors
Enrollment
49 pts
Location
Japan
Sponsor
Toray Industries, Inc
View Trial →
NCT06394622 Phase 1
Recruiting
A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
Enrollment
12 pts
Location
China
Sponsor
Fudan University
View Trial →
NCT06106360
Recruiting
A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy
Enrollment
100 pts
Location
United States
Sponsor
Inova Health Care Services
View Trial →
NCT06644300 Phase 1
Recruiting
Study of BM230 in Patients With Advanced Solid Tumors
Enrollment
123 pts
Location
Australia, China
Sponsor
Suzhou Biomissile Pharmaceutic...
View Trial →
NCT06589401 Phase 1
Recruiting
Oral Paclitaxel for Patients with Advanced Solid Tumors
Enrollment
70 pts
Location
Spain
Sponsor
InnoUp Farma S.L.
View Trial →
NCT05661201 Phase 1
Recruiting
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
Enrollment
24 pts
Location
United States
Sponsor
Georgetown University
View Trial →
NCT06383598
Recruiting
PD-L1 Specific [68Ga]Ga-THP-PDL1-3 Probe for PET Imaging in Solid Tumors
Enrollment
50 pts
Location
China
Sponsor
Hua Zhu
View Trial →
NCT05144698 Phase 1, Phase 2
Recruiting
RAPA-201 Therapy of Solid Tumors
Enrollment
37 pts
Location
United States
Sponsor
Rapa Therapeutics LLC
View Trial →
NCT03866525 Phase 1, Phase 2
Recruiting
OH2 Oncolytic Viral Therapy in Solid Tumors
Enrollment
300 pts
Location
China
Sponsor
Binhui Biopharmaceutical Co., ...
View Trial →
NCT07382544 Phase 1
Recruiting
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
Enrollment
36 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT06403735 Phase 1
Recruiting
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
Enrollment
250 pts
Location
China
Sponsor
Qilu Pharmaceutical Co., Ltd.
View Trial →

Related Conditions

colorectal cancer (4) advanced solid tumor (3) breast cancer (3) solid tumor adult (3) metastatic solid tumor (2) cancer (2) ovarian cancer (2) lung cancer (2) metastatic cancer (2) triple negative breast cancer (2) progesterone receptor positive breast cancer (2) hormone receptor negative breast carcinoma (2)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology